Verrica Pharmaceuticals Inc. (NASDAQ:VRCA - Get Free Report) has been given an average rating of "Moderate Buy" by the five ratings firms that are covering the company, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $11.75.
VRCA has been the subject of several analyst reports. Needham & Company LLC restated a "hold" rating and issued a $12.00 target price on shares of Verrica Pharmaceuticals in a research note on Thursday, October 3rd. Royal Bank of Canada dropped their price target on shares of Verrica Pharmaceuticals from $13.00 to $11.00 and set an "outperform" rating for the company in a research report on Friday, October 4th. TD Cowen decreased their target price on Verrica Pharmaceuticals from $15.00 to $10.00 and set a "buy" rating for the company in a research report on Monday. Finally, Brookline Capital Management reaffirmed a "hold" rating on shares of Verrica Pharmaceuticals in a research report on Wednesday, October 2nd.
View Our Latest Stock Analysis on VRCA
A number of institutional investors and hedge funds have recently bought and sold shares of the business. Simplify Asset Management Inc. acquired a new position in Verrica Pharmaceuticals in the 2nd quarter valued at about $2,041,000. Vanguard Group Inc. grew its holdings in shares of Verrica Pharmaceuticals by 0.6% in the first quarter. Vanguard Group Inc. now owns 1,268,710 shares of the company's stock valued at $7,511,000 after purchasing an additional 7,609 shares in the last quarter. Quest Partners LLC purchased a new stake in Verrica Pharmaceuticals during the 2nd quarter worth approximately $50,000. Key Financial Inc acquired a new position in shares of Verrica Pharmaceuticals in the second quarter worth $69,000. Finally, Renaissance Technologies LLC purchased a new position in Verrica Pharmaceuticals in the second quarter valued at $332,000. 42.45% of the stock is currently owned by institutional investors and hedge funds.
Verrica Pharmaceuticals stock traded down $0.04 during mid-day trading on Monday, reaching $1.57. The stock had a trading volume of 262,524 shares, compared to its average volume of 436,819. The firm has a market capitalization of $66.39 million, a PE ratio of -0.90 and a beta of 1.45. The stock's 50-day simple moving average is $2.09 and its 200-day simple moving average is $5.63. The company has a debt-to-equity ratio of 29.58, a quick ratio of 2.23 and a current ratio of 2.36. Verrica Pharmaceuticals has a fifty-two week low of $1.04 and a fifty-two week high of $11.41.
Verrica Pharmaceuticals (NASDAQ:VRCA - Get Free Report) last issued its quarterly earnings data on Wednesday, August 14th. The company reported ($0.37) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.43) by $0.06. Verrica Pharmaceuticals had a negative net margin of 625.06% and a negative return on equity of 591.84%. The business had revenue of $5.18 million during the quarter, compared to the consensus estimate of $4.70 million. On average, sell-side analysts forecast that Verrica Pharmaceuticals will post -1.58 EPS for the current fiscal year.
Verrica Pharmaceuticals Inc, a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Verrica Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Verrica Pharmaceuticals wasn't on the list.
While Verrica Pharmaceuticals currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.